6.19
+0.11(+1.81%)
Currency In USD
| Previous Close | 6.08 |
| Open | 6.08 |
| Day High | 6.39 |
| Day Low | 6.06 |
| 52-Week High | 7.37 |
| 52-Week Low | 2.41 |
| Volume | 854,831 |
| Average Volume | 1.05M |
| Market Cap | 482.26M |
| PE | -2.5 |
| EPS | -2.48 |
| Moving Average 50 Days | 5.94 |
| Moving Average 200 Days | 5.31 |
| Change | 0.11 |
If you invested $1000 in Solid Biosciences Inc. (SLDB) since IPO date, it would be worth $18.24 as of February 14, 2026 at a share price of $6.19. Whereas If you bought $1000 worth of Solid Biosciences Inc. (SLDB) shares 5 years ago, it would be worth $56.92 as of February 14, 2026 at a share price of $6.19.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy
GlobeNewswire Inc.
Feb 09, 2026 1:00 PM GMT
- IMPACT DUCHENNE: Company aligned with FDA on Phase 3 randomized, double-blind, placebo-controlled trial design -- IMPACT DUCHENNE: Company anticipates first participant dosing in Q1 2026 - - Company plans for additional meetings with the FDA in 1H
Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
GlobeNewswire Inc.
Feb 06, 2026 1:00 PM GMT
CHARLESTOWN, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo C
Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101
GlobeNewswire Inc.
Jan 13, 2026 9:15 PM GMT
- Duchenne: Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026; SGT-003 continues to be generally well tolerated using a steroid-only prophylactic immunomodulation regimen - - Duchenne: First participant enro